IT distribution giant Ingram Micro (NYSE:INGM) reported Q3 CY2025 results exceeding the market’s revenue expectations, with ...
Alnylam Pharmaceuticals, Inc. is rated Hold due to high expectations, competitive threats, and revenue expansion. Learn more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback